Dr. Kayla Secrest's experience with a sepsis-detection algorithm at a Michigan hospital illustrates a growing crisis in medical AI: tools that perform well in labs often fail in real clinical settings. The algorithm generated constant false alerts, leading Secrest and colleagues to ignore notifications entirely — a "boy who cried wolf" scenario. Only later did she learn it had been deployed to hundreds of hospitals without rigorous real-world testing.

Experts warn of a dangerous gap between AI developers and frontline healthcare. Jess Morley of the Yale Digital Ethics Centre notes companies prioritize "statistical validation" over clinical efficacy, with "shockingly poor evidence that AI actually makes an impact on patient outcomes." Regulatory gaps and insufficient performance data compound the problem.

Advocates cite administrative benefits: Nvidia's Kimberly Powell highlights automated note-taking, while OpenAI reports 80% administrative time reduction at Advent Health and 16% fewer diagnostic errors at Kenya's Penda Health. Eric Topol of Scripps Research Translational Institute confirms proven value in diagnostics, citing a 2024 study where AI-assisted colonoscopies detected substantially more polyps.

However, Topol warns healthcare leaders are captivated by generative AI's "wow factor" rather than adopting tools with proven records. The imperative remains establishing the benefit-to-harm ratio before widespread deployment.